Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
– Educational resources help caregivers of the estimated 2.4 million people living with dementia-related hallucinations and delusions identify and discuss symptoms
“As a leading, national caregiver organization, we hear from dementia caregivers every day about the challenges they experience caring for loved ones with behavioral symptoms of dementia. This new resource provides information and support to address these symptoms that can have a devastating impact on families,” said
MoreThanMemoryLoss.com was developed following extensive caregiver research and input from advocacy organizations. The site offers educational and actionable resources for visitors, including a doctor discussion guide, a dementia-related hallucinations and delusions fact sheet and an adapted personal story from a caregiver coping with a loved one’s experience of these symptoms.
Dementia affects 8 million people in the
“Caregivers often believe their job is to protect the image of their loved one and to hide the symptoms of dementia-related psychosis from others,” said
Visit https://www.morethanmemoryloss.com to learn more, and sign up for additional educational resources.
About Dementia-Related Psychosis
Approximately 8 million people in
It is estimated that 2.4 million Americans (or 30% of people with dementia) experience dementia-related hallucinations and delusions. These symptoms may be frequent and severe and may recur over time. A hallucination is defined as a perception-like experience that occurs without an external stimulus and is sensory (seen, heard, felt, tasted, sensed) in nature. A delusion is defined as a false, fixed belief that is resolutely held despite evidence to the contrary. Dementia-related psychosis occurs in many types of dementia, including Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease dementia, vascular dementia, and frontotemporal dementia. Serious consequences have been associated with psychosis in patients with dementia, such as repeated hospital admissions, increased likelihood of nursing home placement, progression of dementia, and increased risk of morbidity and mortality.8
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.
1Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in
2Goodman RA, Lochner KA, Thambisetty M, et al. Prevalence of dementia subtypes in
3Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in
4Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2020;16(3):391-485
52017 Alzheimer’s Disease Facts and Figures and Acadia market research.
6Lopez O, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2003;153:346-353.
8Connors MH et al. Am J Geriatr Psychiatry 2018;26(3). Peters ME et al. Am J Psychiatry 2015;172(5). Haupt M et al. Int J Geriatr Psychiatry 1996;11(11). Naimark D et al. J Am Geriatr Soc 1996;44(3). Stern Y et al. Neurology 1994;44(12).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210219005133/en/